Tag:

Valeant

Latest Headlines

Latest Headlines

Analysts: Actavis-Allergan deal could create a marketing superpower

Valeant's been pursing Allergan for months now, but the California-based drugmaker may soon have another bid, too.

Buzz: Unsated by its Durata deal, Actavis looks again to buy Allergan

Fresh off signing up to buy Durata Therapeutics for $675 million, Actavis is making another overture for the embattled Allergan, Reuters reports, potentially setting up a bidding war with the dogged Valeant Pharmaceuticals.

UPDATED: With Actavis poised to swoop in, Valeant eyes $4.5B hike in bid for Allergan

Valeant CEO J. Michael Pearson has said he's confident Allergan shareholders will vote in support of his company's hostile bid come December. But it never hurts to have a little insurance.

Allergan asks judge to nix Ackman's voting rights at special meeting

Allergan's still okay with holding a special shareholder meeting on Dec. 18, a date it last month agreed on with wannabe acquirer Valeant. It just doesn't want its pursuer's partner, Bill Ackman, to have a say.

FDA slaps Valeant with a warning letter. Will Allergan slap it, too?

Tuesday, Valeant Pharmaceuticals said the FDA had served up a warning letter about its Sculptra Aesthetic manufacturing, citing problems it observed during a June 2014 inspection. The missteps from manufacturing standards might just fuel the fire from hostile buyout target Allergan.

Valeant hit with FDA warning letter for CMO oversight shortcomings

Valeant Pharmaceuticals has grown quickly over the past few years as it has pursued, bought and divested pharmaceutical assets. But somewhere along the way oversight of a supplier slipped. The FDA spotted the problems during a recent visit to Valeant's U.S. headquarters, leading to the posting of a warning letter.

UPDATED: Allergan's next tug-of-war move: Attack Valeant's rosy Q3 forecast

Allergan may or may not bow to requests from some of its largest shareholders to wait on M&A until after December's special meeting. But in the meantime, it's continuing its barrage on predator Valeant's sales model, which it says will yield a tough Q4.

Allergan buy Salix? Not so fast, say investors intent on Valeant vote

Valeant Pharmaceuticals isn't the only one who thinks Allergan should hold off on dealmaking till shareholders say their piece at a December special meeting. Three top-15 Allergan shareholders are urging the Botox maker to delay until investors weigh in on Valeant's hostile bid.

Valeant adds activist shareholder Ubben to board as Allergan takeover bid heats up

In yet another sign that it's not about to abandon its hostile bid to buy Allergan, Valeant has named activist investor Jeffrey Ubben to its board. Ubben is chief executive officer of ValueAct Capital Management, Valeant's second-largest shareholder and a new supporter of the Allergan deal.

Valeant talks up the billion-dollar potential of its Phase III eye drug

Valeant Pharmaceuticals is famous for its aversion to pharmaceutical R&D, but the serial acquirer makes an exception when it sees blockbuster promise in a late-stage asset. And that's the case for the glaucoma treatment Vesneo, which met its goals in pivotal trials and, according to the company, has blockbuster potential.